Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.11, n.12, article ID e0166380, 13p, 2016
Resumo
Backgrounds Our aim was to evaluate the role of 20 genetic polymorphisms in the development and prognosis of sporadic and familial PC. A case-control study of 185 patients who underwent radical prostatectomy from 1997 to 2011. These patients were divided into two groups based on their family history. Gleason grade, PSA value and pathological TNM 2002 stage were used as prognostic factors. Blood samples from 70 men without PC were used as controls. The SNPs were genotyped using a TaqMan SNP Genotyping Assay Kit. Results Considering susceptibility, the polymorphic allele in the SNP rs2660753 on chromosome 3 was significantly more prevalent in controls (p = 0.01). For familial clustering, the polymorphic homozygote genotype of the SNP rs7931342 was five times more frequent in patients with familial PC compared to sporadic PC (p = 0.01). Regarding the SNP 1447295, the polymorphic homozygote genotype was more prevalent in patients with organ-confined PC (p = 0.05), and most importantly, the polymorphic allele occurred more frequently in patients without biochemical recurrence (p = 0.01). Kaplan-Meier analysis showed a median biochemical recurrence free survival of 124.2 compared to 85.6 months for patients with the wild-type allele (p = 0.007). Conclusion Our findings provide the evidence for the association of 20 recently highlighted SNPs and their susceptibility, familial clustering, staging, Gleason score and biochemical recurrence of PC. We believe that the association between these SNPs and PC may contribute to the development of alternative tools that can facilitate the early detection and prognosis of this disease.
Palavras-chave
Referências
- Baade PD, 2009, MOL NUTR FOOD RES, V53, P171, DOI 10.1002/mnfr.200700511
- CARTER BS, 1993, J UROLOGY, V150, P797
- Cody NAL, 2009, MOL CARCINOGEN, V48, P1077, DOI 10.1002/mc.20535
- Cussenot O, 1996, PATHOL BIOL, V44, P737
- Du MJ, 2015, HUM MOL GENET, V24, P154, DOI 10.1093/hmg/ddu426
- Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90
- Huang SP, 2009, CANCER EPIDEM BIOMAR, V18, P3068, DOI 10.1158/1055-9965.EPI-09-0665
- Kote-Jarai Z, 2008, CANCER EPIDEM BIOMAR, V17, P2052, DOI 10.1158/1055-9965.EPI-08-0317
- Liu H, 2011, PROSTATE, V71, P209, DOI 10.1002/pros.21235
- MEIKLE AW, 1985, PROSTATE, V6, P121
- Siegel RL, 2015, CA-CANCER J CLIN, V65, P457, DOI 10.3322/caac.21314
- Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
- Simard J, 2002, ENDOCRINOLOGY, V143, P2029, DOI 10.1210/en.143.6.2029
- Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371
- SPITZ MR, 1991, J UROLOGY, V146, P1305
- STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409
- Teerlink CC, 2014, HUM GENET, V133, P347, DOI 10.1007/s00439-013-1384-2
- Waters KM, 2009, CANCER EPIDEM BIOMAR, V18, P1285, DOI 10.1158/1055-9965.EPI-08-1142
- Zhang YR, 2012, ASIAN PAC J CANCER P, V13, P6273, DOI 10.7314/APJCP.2012.13.12.6273
- Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819
- Zhou Lin, 2011, Zhonghua Nan Ke Xue, V17, P682